Eton Pharmaceuticals, Inc.
ETON
$30.53
$0.581.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 79.89% | 104.94% | 102.77% | 85.40% | 40.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.89% | 104.94% | 102.77% | 85.40% | 40.88% |
| Cost of Revenue | 76.29% | 113.19% | 124.41% | 76.26% | 73.22% |
| Gross Profit | 82.44% | 99.44% | 87.93% | 91.63% | 24.39% |
| SG&A Expenses | 38.56% | 57.75% | 61.40% | 54.88% | 40.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.15% | 85.13% | 75.58% | 52.34% | 48.63% |
| Operating Income | 454.91% | 269.07% | 105.12% | 112.99% | -441.70% |
| Income Before Tax | 66.94% | -19.70% | -22.18% | 36.94% | -487.50% |
| Income Tax Expenses | -112.36% | 186.67% | 13.71% | -66.45% | -63.97% |
| Earnings from Continuing Operations | 67.82% | -20.35% | -21.91% | 38.27% | -602.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.82% | -20.35% | -21.91% | 38.27% | -602.08% |
| EBIT | 454.91% | 269.07% | 105.12% | 112.99% | -441.70% |
| EBITDA | 14,605.48% | 846.43% | 188.93% | 166.06% | -95.08% |
| EPS Basic | 68.21% | -15.52% | -17.05% | 40.95% | -580.00% |
| Normalized Basic EPS | 172.07% | 99.15% | 36.10% | 64.19% | -439.37% |
| EPS Diluted | 62.19% | -13.62% | -18.44% | 35.86% | -614.52% |
| Normalized Diluted EPS | 155.58% | 85.84% | 36.25% | 64.00% | -460.52% |
| Average Basic Shares Outstanding | 3.16% | 3.89% | 3.51% | 2.73% | 1.83% |
| Average Diluted Shares Outstanding | 10.66% | 7.38% | 2.87% | 3.36% | 2.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |